IL137419A0 - Nk cells activating receptors and their therapeutic and diagnostic uses - Google Patents

Nk cells activating receptors and their therapeutic and diagnostic uses

Info

Publication number
IL137419A0
IL137419A0 IL13741900A IL13741900A IL137419A0 IL 137419 A0 IL137419 A0 IL 137419A0 IL 13741900 A IL13741900 A IL 13741900A IL 13741900 A IL13741900 A IL 13741900A IL 137419 A0 IL137419 A0 IL 137419A0
Authority
IL
Israel
Prior art keywords
therapeutic
diagnostic uses
activating receptors
targeting
complex
Prior art date
Application number
IL13741900A
Other languages
English (en)
Original Assignee
Yissum Res Dev Co
B G Negev Technologies And App
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, B G Negev Technologies And App filed Critical Yissum Res Dev Co
Priority to IL13741900A priority Critical patent/IL137419A0/xx
Priority to AU7866201A priority patent/AU7866201A/xx
Priority to PCT/IL2001/000664 priority patent/WO2002008287A2/en
Priority to JP2002514191A priority patent/JP2004504065A/ja
Priority to AT01956747T priority patent/ATE311464T1/de
Priority to CA002416733A priority patent/CA2416733A1/en
Priority to DE60115452T priority patent/DE60115452D1/de
Priority to EP01956747A priority patent/EP1301605B1/en
Priority to AU2001278662A priority patent/AU2001278662B2/en
Priority to US10/333,481 priority patent/US20040072256A1/en
Priority to IL15370001A priority patent/IL153700A0/xx
Publication of IL137419A0 publication Critical patent/IL137419A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL13741900A 2000-07-20 2000-07-20 Nk cells activating receptors and their therapeutic and diagnostic uses IL137419A0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IL13741900A IL137419A0 (en) 2000-07-20 2000-07-20 Nk cells activating receptors and their therapeutic and diagnostic uses
AU7866201A AU7866201A (en) 2000-07-20 2001-07-19 NK cells activating receptors and their therapeutic and diagnostic uses
PCT/IL2001/000664 WO2002008287A2 (en) 2000-07-20 2001-07-19 Nk cells activating receptors and their therapeutic and diagnostic uses
JP2002514191A JP2004504065A (ja) 2000-07-20 2001-07-19 Ｎｋ細胞活性化受容体並びにその治療上および診断上の使用
AT01956747T ATE311464T1 (de) 2000-07-20 2001-07-19 Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen
CA002416733A CA2416733A1 (en) 2000-07-20 2001-07-19 Nk cells activating receptors and their therapeutic and diagnostic uses
DE60115452T DE60115452D1 (de) 2000-07-20 2001-07-19 Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen
EP01956747A EP1301605B1 (en) 2000-07-20 2001-07-19 Nk cells activating receptors and their therapeutic and diagnostic uses
AU2001278662A AU2001278662B2 (en) 2000-07-20 2001-07-19 NK cells activating receptors and their therapeutic and diagnostic uses
US10/333,481 US20040072256A1 (en) 2000-07-20 2001-07-19 Nk cells activiating receptors and their therapeutic and diagnostic uses
IL15370001A IL153700A0 (en) 2000-07-20 2001-07-19 Nk cells activating receptors and their therapeutic and diagnostic uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL13741900A IL137419A0 (en) 2000-07-20 2000-07-20 Nk cells activating receptors and their therapeutic and diagnostic uses

Publications (1)

Publication Number Publication Date
IL137419A0 true IL137419A0 (en) 2001-07-24

Family

ID=11074420

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13741900A IL137419A0 (en) 2000-07-20 2000-07-20 Nk cells activating receptors and their therapeutic and diagnostic uses

Country Status (9)

Country Link
US (1) US20040072256A1 (xx)
EP (1) EP1301605B1 (xx)
JP (1) JP2004504065A (xx)
AT (1) ATE311464T1 (xx)
AU (2) AU2001278662B2 (xx)
CA (1) CA2416733A1 (xx)
DE (1) DE60115452D1 (xx)
IL (1) IL137419A0 (xx)
WO (1) WO2002008287A2 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051834A2 (en) * 2001-12-14 2003-06-26 President And Fellows Of Harvard College Immunocellular receptors related to neurological disorders
JP2006516094A (ja) * 2002-11-08 2006-06-22 ジェネンテック・インコーポレーテッド ナチュラルキラー細胞関連疾患の治療のための組成物と方法
US20060165592A1 (en) * 2002-12-09 2006-07-27 Ofer Mandelboim Nk cell receptor conjugates for treating malignancies
EP1445614A1 (en) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for the in vitro assessment of the progression status of an HIV virus in an invidual
GB0305478D0 (en) 2003-03-10 2003-04-16 Bioxell Spa Diagnostic and prognostic compounds and method
US7825085B2 (en) 2003-06-30 2010-11-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fragments of NKp44 and NKp46 for targeting viral-infected and tumor cells
US20070280938A1 (en) * 2003-11-25 2007-12-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Peptides Derived from Natural Cytotoxicity Receptors and Methods of Use Thereof
CA2558733C (en) * 2004-02-06 2016-04-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
WO2006103569A2 (en) * 2005-03-18 2006-10-05 Innate Pharma Expression vectors and methods for obtaining nk cell specific expression
WO2007147901A1 (en) * 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US7932055B2 (en) * 2006-06-22 2011-04-26 Novo Nordisk A/S Soluble heterodimeric CD94/NKG2 receptors fusion proteins
WO2009147137A1 (en) * 2008-06-02 2009-12-10 Institut Gustave Roussy NATURAL KILLER p30 (NKp30) DYSFUNCTION AND THE BIOLOGICAL APPLICATIONS THEREOF
EP2408468B1 (en) 2009-03-19 2014-04-30 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. USE OF NKp46 FOR PREVENTING TYPE 1 DIABETES
WO2012175613A1 (en) 2011-06-21 2012-12-27 Innate Pharma NKp46-MEDIATED NK CELL TUNING
EP2828291A1 (en) 2012-03-21 2015-01-28 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Peptides derived from the d1-domain of nkp46
WO2015110831A1 (en) 2014-01-24 2015-07-30 University Court Of The University Of St Andrews Immunomodulatory compounds
CA3016563A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CA3030534A1 (en) 2016-07-11 2018-01-18 The National Institute For Biotechnology In The Negev, Ltd. Fusion proteins with extended serum half life
GB201616007D0 (en) 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Novel Adjuvants
GB201616009D0 (en) 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Treatment and/or prevention of sepsis
GB201616006D0 (en) 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Cell modulation
WO2022184162A1 (zh) * 2021-03-05 2022-09-09 上海齐鲁制药研究中心有限公司 针对NKp46的抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912170A (en) * 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US5641875A (en) * 1993-09-30 1997-06-24 University Of Pennsylvania DNA encoding chimeric IgG Fc receptor
ATE297986T1 (de) * 1995-02-24 2005-07-15 Gen Hospital Corp Neuorientierung der zellulären immunität durch rezeptorchimären
EP0828843A1 (en) * 1995-05-16 1998-03-18 Bristol-Myers Squibb Company Recombinant heregulins and their biological functions upon receptor activation
WO1999023867A2 (en) * 1997-11-07 1999-05-20 Biogen, Inc. Bmog, a protein member of the myelin-oligodendrocyte glycoprotein family and its use

Also Published As

Publication number Publication date
JP2004504065A (ja) 2004-02-12
DE60115452D1 (de) 2006-01-05
AU2001278662B2 (en) 2006-09-28
EP1301605A2 (en) 2003-04-16
AU7866201A (en) 2002-02-05
EP1301605B1 (en) 2005-11-30
WO2002008287A2 (en) 2002-01-31
CA2416733A1 (en) 2002-01-31
WO2002008287A3 (en) 2002-12-19
US20040072256A1 (en) 2004-04-15
ATE311464T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
AU7866201A (en) NK cells activating receptors and their therapeutic and diagnostic uses
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
EP1732602A4 (en) CYTOTOXIC MEDIATION OF CELLS WITH SUPERFICIAL EXPRESSION OF MCSP
GB2453677A (en) Lumen-traveling biological interface device
AR055223A1 (es) Caracterizacion y compensacion de electrodos del ecg
CY1110681T1 (el) Θεραπεια me anti-cd20 αντισωμα ασθενων που λαμβανουν μοσχευματα βμτ ή pbsc
DK1449850T3 (da) Humane CDR-graftede antistoffer eller antistoffragmenter deraf
AU2001295531A1 (en) Antisense oligonucleotides against vanilloid receptor 1
IL129299A0 (en) Monoclonal antibodies antigens and diagnosis of malignant diseases
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
YU42703A (sh) Jedinjenja specifična za dobijanje adenozinske a1,a2a i a3 receptore i njihove primene
ITRM20010408A0 (it) Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
ATE411833T1 (de) Vorrichtung zum abliefern von pharmazeutika an das innenohr
EP1778351A4 (en) VERIFICATION OF LESIONAL FEATURES WITH BEAM SHAPES
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
WO2005030797A3 (en) Melanocortin receptor agonists
GB2449044A (en) Cytotoxicity mediation of cells evidencing surface expression of cd63
EP1708751A4 (en) METHOD OF KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGEN EXPOSED ON APOPTOTIC TUMOR CELLS
ATE497976T1 (de) Spezifisch an vygfvracl-hla-a24 bindende t-zellen-rezeptoren
DOP2009000208A (es) Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana
AU2002246668A1 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
EP1667716B8 (en) Cytotoxicity mediation of cells evidencing surface expression of cd44
HUP0301812A2 (hu) Átvizsgálási (screening) eljárás
MX2009001014A (es) Mediacion de citotoxicidad de celulas que evidencian expresion de cd63 en superficie.
WO2007093451A3 (en) Multimodal imaging using a three compartment polymer nanoparticle with cell specificity